Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	25.11B -11.8%
Revenue (ttm)	4.74B -16.9%
Net Income	935.80M -32.0%
EPS	0.42 -31.2%
Shares Out	2.23B
PE Ratio	26.95
Forward PE	28.87
Dividend	0.27 (2.39%)
Ex-Dividend Date	Jun 10, 2025

Volume	27,837,090
Average Volume	21,503,649
Open	10.62
Previous Close	10.72
Day's Range	10.60 - 11.29
52-Week Range	9.71 - 14.74
Beta	0.19
RSI	53.56
Earnings Date	Mar 31, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; urso...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,184
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.